You are here

Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ankylosing Spondylitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Diagnosis of ankylosing spondylitis, as defined by Modified New York Criteria for
Ankylosing Spondylitis.

2. Maintained inflammatory activity for more than 12 weeks defined by:·Axial forms:
BASDAI higher than or equal to 4 (0-10) and at least one of the following parameters:.
Global assessment of the disease by the patient higher than or equal to 4 (On a scale
0-10). Spinal pain higher than or equal to 4 on a visual analogue scale (VAS).
Increase in erythrocyte sedimentation rate (ESR) and/or CRP above the normality
parameters established by the laboratory.·Peripheral forms: Arthritis or enthesitis
higher than or equal to 1 site and at least one of the following:. Global assessment
of the disease by the patient higher than or equal to 4 (on a scale 0-10). Increase in
erythrocyte sedimentation rate (ESR) and/or CRP above the normality parameters
established by the laboratory

3. Failure to treatment: Failure to at least 2 NSAIDs at maximum recommended dose during
at least 3 months (or a shorter time in case of intolerance, toxicity or
contraindication).·In cases of ankylosing spondylitis with peripheral joint
involvement, salazopyrine should have been used at a dose of 2-3 g per day and/or
methotrexate (15 mg/week) for 4 months (or a shorter time in case of intolerance,
toxicity or contraindication). In case of oligoarticular or localized involvement in
enthesis: lack of response, at the discretion of the investigator, to local
infiltrations and/or synoviorthesis.

4. Be between 18-70 years of age

5. Negative result of a pregnancy test in serum in screening visit and in urine in
baseline visit, done in all women, except those surgically sterilized and those who
have at least one year of menopause.

6. Sexually active women of childbearing potential must use medically acceptable
contraceptive methods, including oral, injectable or implantable contraceptive
methods, intrauterine devices or properly used barrier contraception. A woman of
childbearing potential is defined as one who is biologically capable of becoming
pregnant. This includes women who are using contraceptives or whose sexual partners
are either sterile or using contraceptives.

7. Men who are not surgically sterile should agree to use reliable contraceptive methods
during the study.

8. Ability to reconstitute the drug and self-inject it or have a person who can do so.

9. Capability to understand and voluntarily give written informed consent that is signed
and dated, before any specific procedure of the protocol is performed.

10. Ability to store injectable test article at 2º to 8º C.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Contraindications for treatment with anti-TNF

2. Complete ankylosis of spine

3. Onset of treatment with DMARDs in the 4 weeks prior to baseline (SSZ, MTX and HCQ are
permitted if the administrated dose has been maintained stable in the 4 weeks prior to
baseline). Furthermore, patients with a dose of prednisone >10 mg/d or equivalent or
modified in the 2 weeks prior to the baseline visit, those in whose infiltration has
been performed with intraarticular corticosteroids has been performed in the 4 weeks
prior to the screening visit and those who follow treatment with more than one NSAID
in the 2 weeks prior to the baseline visit are excluded.

4. Previous treatment with other TNF inhibitors and other biological drugs

5. Abnormalities in hematology profiles defined by:

- leukocytes lower than or equal to 3.5 x 10 exponent 9 /L

- hemoglobin lower than or equal to 8.5 g/L or 5.3 mmol/L

- hematocrit lower than or equal to 27%

- platelets lower than or equal to 125 x 10 exponent 9 /L

- serum creatinine higher than or equal to 175 mmol/L

- aspartate aminotransferase and alanine aminotransferase higher than or equal to 2
times the upper limit of normality

6. Important concomitant medical conditions, such as:-Class III or IV congestive heart
failure according to New York Heart Association classification-Uncontrolled arterial
hypertension (defined as screening systolic blood pressure > 160 mm Hg or screening
diastolic blood pressure > 100 mm Hg)-Myocardial infarction within 12 months of the
screening visit or unstable angina-Severe pulmonary disease requiring hospitalization
or oxygen therapy-Diagnosis of multiple sclerosis or other central nervous system
demyelinating disease -Presence or history of confirmed blood dyscrasias-Cancer or
history of cancer (other than resected cutaneous basal cell or squamous cell
carcinoma)-Serious infection (infection requiring hospitalization and/or intravenous
antibiotics) within 1 month of administration of test article administration or active
infection at screening or history of recurrent or chronic infection-Open cutaneous
ulcers-Patients with known chronic infections as positivity to HIV, hepatitis B
surface antigen (HBsAg), or hepatitis C virus (HCV) -Active tuberculosis infection
(local guidelines for appropriate screening and treatment of tuberculosis in the
setting of anti-TNF therapy must be followed)- Any condition that, in the
investigator's judgment, might cause this study to be detrimental to the subject

7. Pregnant or breast-feeding women

8. Past or current psychiatric illness that would interfere with the subject's ability to
comply with protocol requirements or give informed consent.

9. Treatment with any live (attenuated) vaccine within 4 weeks prior to baseline.

10. History of alcohol or drug abuse that would interfere with the subject's ability to
comply with protocol requirements.

11. Treatment with any investigational drug within 3 months of screening visit.

NCT00873730
Pfizer
Completed
Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Ankylosing Spondylitis
NCT03502616
All Genders
18+
Years
Multiple Sites
Crohn Desease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
NCT02925338
All Genders
6+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now